The funding will support a two-year programme to develop and automate GyreOx’s proprietary drug discovery platform, MACRO.
LifeArc boosts investment in Cambridge University spin-out PolyProx Therapeutics to advance new class of cancer medicines
The investment will help advance studies to validate polyproxin® molecules as potential drug candidates across a range of cancers.
LifeArc and Scottish Government Chief Scientist Office launch new funding scheme to boost translational research in Scotland
Funding aims to progress strong discovery science to a point where additional substantive funding could be secured.
Translational research can turn promising science into new treatments for those with rare diseases. It’s why we…
LifeArc celebrates the UN’s International day of Women and Girls in Science, joining the call to remove any barriers that hold women back.
£1m for translational research projects focussed on children’s rare diseases
Graham Duce appointed to the newly created role of CIO to ensure that we have a sustainable approach to income generation